Literature DB >> 11147596

The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy.

J B Epstein1, M Gorsky, A Guglietta, N Le, S T Sonis.   

Abstract

BACKGROUND: Epidermal growth factor (EGF) is present in biologic fluids, including saliva, and plays a role in maintenance of the epithelial barrier and in healing of damaged mucosa. The purpose of this study was to assess the relation between salivary EGF and the severity of oral mucositis in patients with carcinoma of the head and neck during radiation therapy.
METHODS: Whole resting saliva (WRS) and whole stimulated saliva (WSS) were collected prior to radiation and each week during radiation treatment for 11 men and 7 women. Oral mucositis was evaluated using the National Cancer Institute (NCI) scale of 0-4 and the Oral Mucositis Assessment Scale (OMAS), which evaluates the extent of erythema (scale of 0-2) and ulcerations (scale of 0-3) in nine oral sites. The overall OMAS score of 0-45 reflected the mucosal condition. EGF was assayed in the saliva specimens.
RESULTS: The total mean radiation dose delivered to the head and neck was 5667 centigrays (cGy) in a mean of 24 fractions. Ulcerative oral mucositis occurred in 94% of patients. The mean OMAS score ranged from 2.83 in the first week of treatment to 14.77 in the fifth week. The mean WRS and WSS volumes decreased significantly from pretreatment to the first week of radiation treatment and then remained stable. A similar pattern was seen for the mean total output of EGF. A significant and negative correlation was found between higher levels of EGF in stimulated saliva and low OMAS score, reflecting less severe erythema and ulceration. A general trend showing that less tissue damage was associated with a higher EGF level in resting saliva also was illustrated. EGF levels were correlated with the OMAS score; however, no correlation was found when assessing the NCI score, which combines tissue damage with function and symptoms in a single score.
CONCLUSIONS: Radiation-induced mucositis appeared to be modified by saliva volume, total EGF, and concentration of EGF in the oral environment. Saliva volume and total EGF output decreased significantly in the first weeks of treatment and remained reduced throughout radiation therapy. The findings suggest that higher levels of EGF in saliva, particularly in stimulated saliva, prior to and during radiation treatment may be associated with less severe mucosal damage due to radiation therapy. It is also postulated that human EGF may affect the development and healing of radiation-damaged mucosa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147596     DOI: 10.1002/1097-0142(20001201)89:11<2258::aid-cncr14>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer.

Authors:  Rajesh V Lalla; Linda E Choquette; Kathleen F Curley; Robert J Dowsett; Richard S Feinn; Upendra P Hegde; Carol C Pilbeam; Andrew L Salner; Stephen T Sonis; Douglas E Peterson
Journal:  Oral Oncol       Date:  2014-08-21       Impact factor: 5.337

Review 2.  Biomarkers in the assessment of oral mucositis in head and neck cancer patients: a systematic review and meta-analysis.

Authors:  Ana Gabriela Costa Normando; Camila Lopes Rocha; Isabela Porto de Toledo; Paulo Tadeu de Souza Figueiredo; Paula Elaine Diniz Dos Reis; Graziela De Luca Canto; Eliete Neves Silva Guerra
Journal:  Support Care Cancer       Date:  2017-06-16       Impact factor: 3.603

3.  Randomized control trial of benzydamine HCl versus sodium bicarbonate for prophylaxis of concurrent chemoradiation-induced oral mucositis.

Authors:  Imjai Chitapanarux; Tharatorn Tungkasamit; Janjira Petsuksiri; Danita Kannarunimit; Kanyarat Katanyoo; Chakkapong Chakkabat; Jiraporn Setakornnukul; Somying Wongsrita; Naruemon Jirawatwarakul; Chawalit Lertbusayanukul; Patumrat Sripan; Patrinee Traisathit
Journal:  Support Care Cancer       Date:  2017-09-23       Impact factor: 3.603

Review 4.  Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis.

Authors:  Inger von Bültzingslöwen; Michael T Brennan; Fred K L Spijkervet; Richard Logan; Andrea Stringer; Judith E Raber-Durlacher; Dorothy Keefe
Journal:  Support Care Cancer       Date:  2006-04-21       Impact factor: 3.603

Review 5.  Anti-inflammatory agents in the management of alimentary mucositis.

Authors:  Rajesh V Lalla; Mark M Schubert; Rene-Jean Bensadoun; Dorothy Keefe
Journal:  Support Care Cancer       Date:  2006-03-25       Impact factor: 3.603

Review 6.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-17       Impact factor: 3.603

Review 7.  Management of oral mucositis in patients who have cancer.

Authors:  Rajesh V Lalla; Stephen T Sonis; Douglas E Peterson
Journal:  Dent Clin North Am       Date:  2008-01

8.  The combined effect of recombinant human epidermal growth factor and erythropoietin on full-thickness wound healing in diabetic rat model.

Authors:  Joon Pio Hong; Sung Woo Park
Journal:  Int Wound J       Date:  2012-10-19       Impact factor: 3.315

9.  Long-term oral Candida colonization, mucositis and salivary function after head and neck radiotherapy.

Authors:  K A Grötz; S Genitsariotis; D Vehling; B Al-Nawas
Journal:  Support Care Cancer       Date:  2003-08-09       Impact factor: 3.603

10.  The use of recombinant human epidermal growth factor to promote healing for chronic radiation ulcer.

Authors:  Sang-wook Lee; Sue Young Moon; Yeun Hwa Kim; Joon Pio Hong
Journal:  Int Wound J       Date:  2007-09       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.